Aoxiang Pharmaceutical announced that recently, the company received the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” for pibasilil APIs and dagliflozin APIs approved and issued by the State Drug Administration. Pibacilli is a cyclin-dependent kinase CDK4/6 inhibitor suitable for treating locally advanced or metastatic breast cancer with positive hormone receptors and negative human epidermal growth factor receptor 2. Dapagliflozin is a novel oral hypoglycemic agent in the class of sodium-glucose co-transporter protein-2 inhibitors. It can be used as a single drug treatment or combination treatment to improve blood sugar control based on diet and exercise.

Aoxiang Pharmaceutical announced that recently, the company received the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” for pibasilil APIs and dagliflozin APIs approved and issued by the State Drug Administration. Pibacilli is a cyclin-dependent kinase CDK4/6 inhibitor suitable for treating locally advanced or metastatic breast cancer with positive hormone receptors and negative human epidermal growth factor receptor 2. Dapagliflozin is a novel oral hypoglycemic agent in the class of sodium-glucose co-transporter protein-2 inhibitors. It can be used as a single drug treatment or combination treatment to improve blood sugar control based on diet and exercise.